Last reviewed · How we verify
Varicella vaccine+TIV
This combination vaccine stimulates immune responses against varicella-zoster virus and influenza virus through live attenuated or inactivated viral antigens.
This combination vaccine stimulates immune responses against varicella-zoster virus and influenza virus through live attenuated or inactivated viral antigens. Used for Prevention of varicella (chickenpox), Prevention of seasonal influenza.
At a glance
| Generic name | Varicella vaccine+TIV |
|---|---|
| Sponsor | Sinovac (Dalian) Vaccine Technology Co., Ltd. |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The varicella component uses live attenuated varicella-zoster virus to induce cellular and humoral immunity against chickenpox. The TIV (trivalent inactivated influenza vaccine) component contains inactivated influenza virus antigens (typically two A strains and one B strain) that trigger antibody production against seasonal influenza. Together, the combination provides simultaneous protection against both varicella and influenza in a single administration.
Approved indications
- Prevention of varicella (chickenpox)
- Prevention of seasonal influenza
Common side effects
- Injection site reactions (pain, redness, swelling)
- Fever
- Rash
- Myalgia
- Headache
Key clinical trials
- Vaccine Responses in Cancer
- Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children (PHASE4)
- Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion) (PHASE4)
- Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction (PHASE4)
- Study to Assess the Immunogenicity and Safety of GSK's Investigational Vaccine (GSK3277511A) When Given to Healthy Smokers and Ex-smokers After Administration of Shingrix Vaccine (PHASE2)
- Restoration of Immunity to Vaccine Preventable Diseases After CART-T Cell Therapy
- A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine (PHASE3)
- Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |